Robert Gronke, PhDSenior Principal Scientist, Technical Development at Biogen, Inc
Robert Gronke is a Senior Principal Scientist in the Antisense Oligonucleotide department at Biogen, Inc. For the past 31 years, he’s been involved in the purification process development, CMC team leadership, regulatory liaison and new technology assessments for recombinant biopharmaceuticals including Biogen’s commercial products AVONEX (Interferon Beta-1a), a serum-free version of AVONEX, PLEGRIDY (PEG IFN Beta-1a), BENEPALI (Enbrel biosimilar), SPINRAZA (SMA antisense oligonucleotide), APROLIX (Factor IX-Fc), and AMEVIVE (glycosylated fusion protein), along with more than 20 clinical products including monoclonal antibodies, fusion proteins, glycoproteins, antisense oligonucleotides, and conjugates. Rob currently manages a group of 5 associate scientists.
Prior to joining Biogen, Inc., Dr. Gronke was a post-doctoral fellow in the Pharmacology Department at Merck Sharp & Dohme Research Laboratories in West Point, Pennsylvania. He received his Ph.D. degree in Biochemistry from the University of Kansas, Lawrence Kansas. Prior to receiving his Ph.D., he was employed as a Research Associate at the University of Illinois, Chicago. Dr. Gronke received a BS degree in Biochemistry from Northern Illinois University, DeKalb, Illinois.